New in vitro co-culture model study published with citrus flavonoid extract MicrobiomeX®
New in vitro co-culture model study published with citrus flavonoid extract MicrobiomeX®
Press release
British Journal of Nutrition has recently published a new in vitro co-culture model study with a citrus flavonoid extract MicrobiomeX® and its metabolites, hesperetin and naringenin. The novel publication suggests that these citrus flavonoids, as well as their metabolites, may reduce intestinal inflammation.
New in vitro co-culture model study published with citrus flavonoid extract MicrobiomeX®
MicrobiomeX® is a first-in-class Flavobiotic® developed by BioActor, that combines active ingredients from Citrus sinensis and Citrus paradisi. MicrobiomeX® has already been studied and reported to have various beneficial effects on the gut and immunity. MicrobiomeX® consists of standardised citrus flavonoids, that form active metabolites, hesperetin and naringenin, in the gut after being deglycosylated by the gut microbiota.
In the recently published in-vitro study, a validated co-culture system of Caco-2/THP-1 cells as model for intestinal inflammation and cytokine-induced barrier disruption was used to determine the effects of citrus flavonoids and their metabolites on intestinal inflammation.
During the research, cells were treated with citrus flavonoids, their metabolites, or a vehicle control. Additionally, cells were incubated with lipopolysaccharide (LPS), which is known to induce inflammation and deterioration in epithelial integrity.
The conclusion highlights that hesperetin and naringenin significantly reduced NF-kB activity, leading to a reduction in intestinal inflammation. Pro-inflammatory cytokines IL-8, TNF-α and IL-6 were also significantly reduced after hesperetin and naringenin administration.
The mechanism behind this reduction in inflammation can be ascribed to partial inhibition of the NF-κB signalling pathway.
“We are very happy with the results of this study, as we were able to show that both the citrus flavonoids themselves and their metabolites are able to reduce inflammation in the intestine”, says Yala Stevens, CSO of BioActor. “These new scientific insights on MicrobiomeX® will allow us to consolidate its applications to products targeting gut health and immune function”.
About BioActor
BioActor, based at the Maastricht Health Campus, Netherlands, is a life science company that has developed a range of proprietary bioactive ingredients for the nutrition & consumer health industries. The company focuses on the development of plant-based health ingredients for active living and healthy ageing. The goal is to provide the nutrition & consumer health industries with clinically tested innovations that confer a real health benefit to the consumer.
Feel free to contact BioActor via info@bioactor.com for more information on the possibilities MicrobiomeX® has to offer.
Further information can be found on: www.microbiomex.com and www.bioactor.com
What is the TIM-2 system? An in-vitro model of the colon
What is the TIM-2 system? An in-vitro model of the colon
The TIM-2 model is a dynamic gastrointestinal model, which is used for in-vitro research. The TIM-2 model can be used to study changes in the microbiota composition and the production of beneficial molecules in the gut. It resembles the human large intestine, including peristalsis, dialysis, and microorganisms. It is a good model that provides short experiment durations and the studies done with it are highly reproducible.
What is the TIM-2 model?
The TIM-2 (TNO in-vitro) model is a computer-controlled dynamic in-vitro gastrointestinal model of the colon used in research to study changes in the microbiota composition.
This model closely mimics part of the human large intestine, including its microorganisms, peristaltic movements, temperature (37ºC) and acidic pH (5.8).
What is the TIM-2 model used for in research?
The TIM-2 model has a wide range of applications in research. It can be used to study changes in the microbiota composition and production of beneficial molecules such as short-chain fatty acids associated with specific dietary patterns or ingredients and, consequently, to increase human health through the understanding of microbiota.
Due to the health benefits of short-chain fatty acids (SCFA), many studies have focused on carbohydrate fermentation and the subsequent production of SCFA.
However, it has also been used to study the effects of probiotics after antibiotic treatment, fermentation of prebiotic fibres, metabolization of molecules such as flavonoids and even to investigate the differences in microbiota from lean and obese individuals.
Watch the interview with prof. Koen Venema
Difference between TIM-2 model and other in-vitro models
Compared to other in-vitro models, TIM-2 holds some unique features, which allow predicting what would happen in an actual clinical trial.
The way the peristaltic movements are produced in the TIM-2 model gives a better mixing of the components than what would be accomplished by stirring or shaking. Thanks to this, in TIM-2 there is no phase-separation of solids and liquids, which is what occurs in other models.
On the other hand, in vivo microbial metabolites are normally taken up by the gut epithelium. This is, of course, not possible in an in-vitro model, but the TIM-2 model features a unique dialysis system that removes these metabolites produced by microorganisms.
The accumulation of these microbial metabolites would otherwise result in the inhibition or death of the microorganisms present in the model. Therefore, the dialysis system allows maintaining a highly active microbiota, with a similar density to that found in the human intestine.
In other systems, metabolites tend to accumulate. In fact, with the TIM-2 model, since all the microbial metabolites are collected, they can be measured, which is something not possible in a real-life setting.
What are the advantages and limitations of the TIM-2 model?
Advantages of the TIM-2 model include:
• Short experiment duration. Compared to other models, experiments are quick, usually taking three test days or even less.
• Presence of peristaltic movements and dialysis system. These two unique features allow predicting what would happen in an actual clinical trial.
• Single parameter study. If a single parameter in the system is changed, the effect of that parameter on the microbiota can be studied.
• Highly reproducible. Since the model is computer-controlled, it is highly reproducible.
Like other in-vitro models, the TIM-2 model has some limitations, which include:
• Absence of gut epithelial cells, immune cells and neurons. However, samples can be taken and incubated with these kinds of cells to investigate interactions.
• Based mostly on healthy individuals. The model has been developed based on data coming from mostly healthy individuals. For this reason, it is unclear exactly which parameters to adjust when simulating patient populations.
• Absence of feedback mechanisms. Due to this, as with similar in-vitro models, the results will always be an indication of what may occur in real life and, therefore, they should be interpreted carefully.
What are postbiotics? Let's find out!
What are postbiotics? Let’s find out!
Probiotics and prebiotics are very popular nowadays for their positive effects on gut health. Most recently, postbiotics, which are products or metabolites released from microbial fermentation, have also gained attention due to their health benefits. However, they are still unknown to the majority of consumers.
What are postbiotics?
Postbiotics are defined as a “preparation of inanimate microorganisms and/or their components that confers a health benefit on the host”. In other words, they are the bacterial products or metabolites released from microbial fermentation.
For this reason, postbiotics include several types of compounds, such as short-chain fatty acids (that have several health benefits), microbial cell fragments, functional proteins, extracellular polysaccharides, cell lysates or teichoic acid.
Unlike probiotics, postbiotics do not need to be alive to be beneficial, so they are more stable than the living bacteria they are derived from. [1]
Why postbiotics?
Why postbiotics when I can already take probiotics and prebiotics? This may be a question that comes up.
It is important to understand that gut microbiota composition varies between individuals. This means that the degree to which different components are metabolized may be different among persons.
As a result, probiotics and prebiotics may have different health effects between individuals. Moreover, temporal changes in our gut microbiota composition could also influence the effects of these compounds.
On the other hand, many positive health effects of probiotics and prebiotics are due to the production of components such as short-chain fatty acids, microbial fragments, functional proteins or teichoic acid.
As mentioned before, these components are postbiotics, which means that when postbiotics are taken, these components are directly ingested.
If you want to know more about prebiotics, check this article. Or if you are familiar with prebiotics, this article about synbiotics might be for you!
What are the health benefits of postbiotics?
Research suggests that postbiotics may have several health benefits. These include the following:
• Modulation of the microbiota. Postbiotics components such as butyrate, a short-chain fatty acid, are beneficial for gut health. [2]
• Modulation of the immune system. Butyrate can stimulate the production of T cells in the intestine, which helps control immune responses. Other components such as microbial cell wall fragments can increase the production of cytokines, which are chemical messengers that help reduce inflammation and boost immune responses. [2,3]
• Modulation of the metabolism. Propionate, a short-chain fatty acid, can help improve insulin sensitivity and glucose tolerance. On the other hand, butyrate can stimulate the production of an antioxidant called glutathione. [1,2]
• Weight loss aid. Short-chain fatty acids may help weight loss through the modification of eating behaviours. This is due to the release of hormones that increase satiety. [1]
• Reduction of irritable bowel syndrome (IBS) symptoms. A study in 443 individuals with IBS involving orally administered, heat-inactivated Bifidobacterium bifidum, found that the postbiotic substantially alleviated symptoms associated with IBS, such as abdominal pain or discomfort, abdominal bloating and abnormal bowel habits. [4]
• Other potential benefits. Orally administered, inactivated lactic acid bacteria may help eradicate Helicobacter pylori infection, chronic unexplained diarrhoea and the abrogation of the negative effects of stress. [1]
How can I add postbiotics to my diet?
Postbiotics are not as easy to find as probiotics and prebiotics, but they can be purchased in health food stores and online. They are generally considered safe and well-tolerated.
As postbiotics are generated from fermentation by the bacteria in your gut, you can increase postbiotics production by eating foods rich in probiotics and prebiotics. Probiotics can be found in fermented foods and drinks, such as yoghurt, kefir, tempeh or kombucha. Prebiotics can be found in high fibre foods, such as vegetables and whole-grain products.
The health benefits of Aronia Berry: why should you consume this superfruit?
The health benefits of Aronia Berry: why should you consume this superfruit?
Aronia berries are small dark fruits that are becoming increasingly popular amongst health-conscious consumers. Current research suggests that due to their excellent content in micronutrients and antioxidant properties, these berries may provide important health benefits on immune health, cardiovascular function, brain health as well as exhibiting anti-diabetic function.
What is Aronia berry?
Aronia berries, are little dark fruits, belonging to the Rosaceae Family. Aronia is native to easter and North America but it is also commonly found in the Baltic region of Europe where it was introduced in the first half of the 20th century.
The reason why these berries are also called “Chokeberries” is that when consumed fresh off the shrub, they make your mouth tickle due to their incredibly strong tart taste and mouth-drying effect.
Though many people have never heard about them, Aronia berries are becoming increasingly popular among health-conscious consumers and are considered a real superfruit.
What are the health benefits of Aronia berries?
To answer this question we need to first take a step back in the past where, traditionally, Aronia was used by the North American Forest Potawatomi tribe as a cold remedy.
They called these fruits “nîki’mînûn” and used them to make a traditional tea. The reason why Aronia berry was found to be so effective in treating common cold symptoms is probably linked to their extremely powerful antioxidant capacity.
Nowadays, it is well-known that antioxidants in Aronia outperform any other fruits, even elderberries, blueberries, and raspberries.
Aronia berries contain high levels of vitamin C, but the real claim to fame is their high level of polyphenols, anthocyanins and proanthocyanins [1]. These are types of antioxidants that help to fight the damages caused by free radicals in the body, and it is these antioxidants where Aronia berries can have their greatest impact on our health and wellbeing.
In fact, Aronia is considered a real superfruit due to its high level of antioxidant phytonutrients that can be beneficial in many ways.
Research around Aronia berries have focused on several health benefit areas, and there is evidence to suggest that these fruits may have the potential to:
- Strengthen the immune system [2].
- Improves cardiovascular function [3].
- Improve brain health [4].
- Help against metabolic syndrome [5].
- Prevent urinary tract infections [6].
Nutritional Facts
Aronia berries are low-calories fruits, full of important micro-nutrients accountable for their numerous health benefits.
100 g of Aronia berries provide the following nutrients [7]:
- Calories: 47.0 (197 Kj)
- Carbs: 9.6 g
- Fat: 0.5g
- Protein: 1.4g
- Fiber: 5.3g
- Vitamin A: 350 IU (7% DV)
- Vitamin C: 21 mg (35% DV)
- Vitamin K: 13.6 mcg (17% DV)
- Manganese: 0.6 mg (32% DV)
Moreover, researchers have identified a total of 7 different anthocyanins in Aronia berries. These include phytocompounds such as cyanidin-3-O-glucoside, a key molecule for brain health. It has been reported that cyanidin-3-O-glucoside exhibits anti-inflammatory, anticarcinogenic and antimutagenic activities, while also enhancing spatial memory, cognition and psychomotor control.
How to get more Aronia berries in your diet
Unfortunately, it is not easy to commonly find fresh Aronia berries on the shelf at the grocery store.
However, there are many alternatives. Especially in specialised stores or online it is possible to buy Aronia in form of frozen or dried fruits, tea, jams, juice and wines.
Another effective way to include Aronia in your diet can be through the use of dietary supplements. This can be a great way to ensure you are getting the most out of the health benefits of Aronia berries.
Curious to know more? Here’s everything you need to know about Aronia berries and brain health!
A new study with Olecol® on attenuating sugar digestion and absorption has been published in a peer reviewed scientific journal.
A new study with Olecol® on attenuating sugar digestion and absorption has been published in a peer reviewed scientific journal.
Press release
The European Journal of Nutrition has published the results of the latest in-vitro and human studies with Olecol®. Olecol® attenuates post-prandial glucose spikes in healthy volunteers through the inhibition of sucrose hydrolysis and glucose transport by oleuropein.
Clinical & In-Vitro benefits of Olecol®
Oleuropein is a major constituent of olive leaves, many studies have shown the beneficial effect on various factors related to diabetes and cardiovascular development. Olecol® is standardized in oleuropein content, highly water-soluble and has already shown in two clinical studies to improve blood lipid profiles in subjects with dyslipidaemia.
The latest research on Olecol® conducted by research of Prof. Gary Williamson from University of Leeds in collaboration with BioActor, evaluated the effect of Olecol® on sugar digestion and absorption.
The researchers at Leeds University first conducted in-vitro experiments to study both carbohydrate digestion enzymes and sugar transporters in vitro. This research demonstrated how these mechanisms can positively modulate postprandial glucose in healthy volunteers consuming different types of carbohydrate. Subsequently, another in vitro study showed that Olecol® inhibited intestinal maltase, human sucrase, glucose transport across Caco-2 monolayers cells, and uptake of glucose by GLUT2 in oocyte cells.
Seven cross-over controlled randomized intervention studies, were performed on young healthy volunteers. Five minutes after either placebo or Olecol® intake, participants were given 109g of white bread (containing 50 g of available carbohydrates). It was shown that the combined action of Olecol® on sucrase and on glucose transport can lead to a significant decrease in peak glucose in healthy volunteers.
The multiple benefits of Olecol® are: improvement of blood lipid control in both subjects with hypercholesterolemia and overweight, strong antioxidant proprieties and attenuation of post- prandial sugar peaks in healthy subjects.
About BioActor
BioActor, based in Maastricht, Netherlands, is a product development company that has developed a range of proprietary bioactive ingredients for the nutrition & healthcare industry. The company focuses on the development of innovative activities that address active living and healthy aging. The goal is to provide the nutrition & healthcare industry with science-based innovations that confer a real health benefit to the consumer.
Feel free to contact us via info@bioactor.com for more information on the possibilities Olecol® has to offer.
Further information can be found on: www.olecol.com
Cordiart® and Bonolive®obtained registration by the Malaysian National Pharmaceutical Regulatory Agency
Cordiart® and Bonolive®obtained registration by the Malaysian National Pharmaceutical Regulatory Agency
Press release
Both Cordiart® and Bonolive® obtained registration by the Malaysian National Pharmaceutical Regulatory Agency. Both finished capsule products of which one containing Cordiart® and the other Bonolive® are now officially registered and can be sold on the Malaysian market.
The Cordiart® and Bonolive® In Malaysia
Cordiart® and Bonolive® containing finished capsule products, named Smoozflo and Bonee Care, have been officially approved and registered in Malaysia by the National Pharmaceutical Regulatory Agency. Cordiart® finished capsule products are registered to be used for improving blood circulation under registration number MAL16110075TC. Bonolive® finished capsule products are registered to be used to strengthen bones and joints under registration number MAL16060038TC.
Both Cordiart® and Bonolive® have been clinically evaluated to have significant effects:
Two studies have shown that Cordiart® provides a triple protection of the arteries by improving arterial flexibility, reduces plaque formation, and lower arterial inflammation. The first study targeted patients with metabolic syndrome and impaired endothelial function, whilst the second study was looking at healthy overweight people. In both studies Cordiart® increased flow-mediated dilation compared to placebo. In addition the second study showed a reduction of the levels of adhesion molecules, responsible for plaque formation, and a reduction of the levels of inflammation markers, reflecting the inflammatory status of the arteries.
A 12-month double-blind, placebo-controlled study on a group of osteopenic patients consuming 250 mg/daily of Bonolive® showed a 32% significant increase in serum osteocalcin levels. This validates that Bonolive® prevents bone loss by strengthening bone metabolism and stimulating bone-building cell activity.
If you are interested in these products please feel free to contact our distributor for the Malaysian market, Membra Health, at info@membra.com.my.
About BioActor
BioActor, based in Maastricht, Netherlands, is a product development company that has developed a range of proprietary bioactive ingredients for the nutrition & healthcare industry. The company focuses on the development of innovative activities that address active living and healthy aging. The goal is to provide the nutrition & healthcare industry with science-based innovations that confer a real health benefit to the consumer.
Feel free to contact us via info@bioactor.com for more information on the possibilities Cordiart® and Bonolive® has to offer.
Further information can be found on: www.cordiart.com and www.bonolive.com
Clinical results published in a leading nutrition journal provide novel evidence supporting the beneficial effect of consumption of citrus flavanones on postprandial endothelial function.
Clinical results published in a leading nutrition journal provide novel evidence supporting the beneficial effect of consumption of citrus flavanones on postprandial endothelial function.
Maastricht, Netherlands, April 6, 2017
Press release
The British Journal of Nutrition has published results revealing that an acute, sole dose of citrus flavanones may counteract the transient decline in endothelial function, 7-hours postprandially. However, no effect was found 2-hours postprandially. This study corroborates findings from the latest clinical study on Cordiart®, a sweet orange extract. Moreover, it was shown that a repeated daily dose of standardized citrus flavanones may impart already 2-hours postprandially, a faster recovery in FMD response as compared to a sole dose.
The Clinical Benefits of Cordiart®
A recently published randomized, controlled, double-masked, crossover study (2017) has evaluated the acute impact (0-7 h) of flavanone-containing (mg) 240 ml beverages (orange juice: 128.9 mg; flavanone-rich orange juice: 272.1 mg; homogenized whole orange: 452.8 mg) on postprandial (Western diet/double meal with 81 g of fat) vascular function among middle-aged healthy men (30-65 years, N=28). Subjects had mild cardiometabolic risk factors with a baseline FMD (flow-mediated dilation) of 4.8 units and fasting lipids in the upper half of the normal range (TAG 0.8-3.2 mmol/l, total cholesterol 6.0-8.0 mmol/l) or BMI 25-32 kg/m2.
After 2-hours postprandially, there was no detected improvement in % FMD for all three interventions, despite differing flavanone concentrations. By 7-hours postprandially, all interventions were able to attenuate temporary impairments in FMD to that of baseline levels (7-hours post intake, P<0.05). This was suggested to be due to probable actions of citrus flavanone metabolites on nitric oxide.
Even though these results are promising, it can also be implied that an individual is exposed to endothelial dysfunction for up to 7-hours. By this time, it is common to have already consumed another meal (Western diet), reflecting that the majority of the day is spent in a postprandial state. This absence of a rapid postprandial effect may also be attributed to low flavanone bioavailability.
The article concludes that a daily intake of citrus flavanones may be an effective dietary strategy and ‘such temporary vascular changes repeated on a daily basis can critically impact long-term vascular health and overall chronic disease risk ’
Given the former, it’s important to have a rapid improvement in endothelial function postprandially. This was shown in a 6-week randomized, double-blind, placebo-controlled study that investigated the effects of a daily repeated intake of 500mg of Cordiart® on endothelial function. Already 2-hours after the consumption of a high-fat meal, 6-weeks of Cordiart® supplementation was shown to significantly increase and recover FMD (mean) by approximately 8.9% when compared to the mean baseline fasting level, in individuals with borderline chronic endothelial impairment (FMD≥3%). Therefore, Cordiart® may provide a faster recovery in FMD response as compared to a sole dose of non-standardized flavanones.
Moreover, orange juice is known to contain a high amount of sugar and is not standardized for active flavonoid content. Overall, Cordiart® provides a standardized dose of flavonoids, serving as an optimal solution for preserving endothelial function and supporting healthy blood flow.
About BioActor
BioActor, based in Maastricht, Netherlands, is a product development company that has developed a range of proprietary bioactive ingredients for the nutrition & healthcare industry. The company focuses on the development of innovative activities that address active living and healthy aging. The goal is to provide the nutrition & healthcare industry with science-based innovations that confer a real health benefit to the consumer.
Feel free to contact us via info@bioactor.com for more information on the possibilities Cordiart® has to offer.
Further information can be found on: www.cordiart.com
Naxus®| Results of a randomized controlled trial on reinforcement of intestinal epithelial barrier by arabinoxylans in overweight and obese subjects published in high impact journal
Naxus®| Results of a randomized controlled trial on reinforcement of intestinal epithelial barrier by arabinoxylans in overweight and obese subjects published in high impact journal
Maastricht, Netherlands, March 8, 2017
Press release
The Clinical Nutrition Journal has published the results of the latest clinical study on the effect of arabinoxylans on gut barrier. Naxus® is a clinically evaluated wheat arabinoxylan concentrate produced by BioActor BV for the support of digestive health. The article concludes that “regular consumption of arabinoxylans results in a more beneficial fermentation profile in overweight and obese individuals.” Such a fermentation profile may lead to improved gut barrier function and immune health.
The Clinical Benefits of Naxus®
In a randomized, double-blind, placebo-controlled study the effect of 6-weeks daily intake of 7.5g or 15g arabinoxylans, supplied as Naxus® by BioActor BV, on intestinal permeability was evaluated.
Obesity and metabolic diseases are associated with alterations in microbial composition and impaired gut barrier. The aims of the study were to investigate the effect of Naxus® on intestinal permeability, on gene transcription and protein expression of tight junctions, intestinal microbiota composition and activity, immune response and metabolic markers in overweight and obese individuals. Modulating gut microbiota composition, which influences its effect on intestinal homeostasis, appears to be a promising strategy to treat and prevent chronic diseases.
Gut biopsy specimens showed an upregulation of gene transcription of tight junction and associated proteins in both the 7.5g and 15g Naxus® group compared to placebo. Moreover, intake of Naxus® significantly decreased fecal pH and increased fecal concentrations of total short-chain fatty acids (SCFAs), acetate, propionate and butyrate, compared to placebo
In conclusion, regular consumption of Naxus® resulted in a more beneficial fermentation, i.e. SCFA, profile in overweight and obese individuals. Such a fermentation profile could translate into improved gut barrier function and immune health. Furthermore, an increased gene transcription of several transmembrane proteins was observed. Finally it was shown that 15g Naxus® might have an anti-inflammatory potential and the intake of Naxus® is well-tolerated.
About BioActor
BioActor, based in Maastricht, Netherlands, is a product development company that has developed a range of proprietary bioactive ingredients for the nutrition & healthcare industry. The company focuses on the development of innovative activities that address active living and healthy aging. The goal is to provide the nutrition & healthcare industry with science-based innovations that confer a real health benefit to the consumer.
Feel free to contact us via info@bioactor.com for more information on the possibilities Naxus® has to offer.
Further information can be found on: www.naxus.nl
BioActor receives EUROSTARS grant for the FlaMeS project “Flavonoids and metabolic syndrome”
BioActor receives EUROSTARS grant for the FlaMeS project “Flavonoids and metabolic syndrome”
Press release
BioActor leads the international FlaMeS-consortium to develop novel in-vitro cell technology and clinical validation of Cordiart® for the prevention of the metabolic syndrome. The FlaMeS consortium is a collaboration between two innovation driven SMEs, BioActor (Netherlands) and AdipoPhyt (France). The project will result in the development and clinical validation of novel 3-D cell assays for adipose tissue development and in the clinical validation of a proprietary citrus flavonoid extract for the improvement of glycaemic control and endothelial function.
The FlaMeS project
BioActor BV announced today that EUREKA has approved the FlaMeS project, submitted by BioActor and AdipoPhYt. The FlaMeS Consortium has two objectives: (1) validating novel 3-D cell-based assays to screen for effects of compounds on adipose tissue development, and (2) clinically test and validate effects of Cordiart®, a citrus peel extract, on markers associated with the metabolic syndrome.
Prevalence of obesity and the metabolic syndrome is rapidly increasing, affecting millions of people in Europe alone. Public health authorities have recognized the need for prevention of these chronic diseases. BioActor addresses this need by developing a unique, natural product for improved functioning of blood vessels, glycemic control and heart health: Cordiart®.
Cordiart® is a natural flavonoid citrus peel extract with optimized bioavailability. This ingredient commands a high content of natural bioactive flavonoids. A number of in-vivo and human studies have shown very promising effects for Cordiart® in use for blood vessel function, glycemic control and heart health.
In order to test novel substances regarding their effects on adipose tissue (fat storage cells), new ‘humanized’ in vitro models are needed. AdipoPhYt is currently developing a cutting edge new technology “AdipoGut”, combining all present techniques and knowledge into a high quality and predictive test system. The FlaMeS project will result in a marketable functional food ingredient “Cordiart®”, with proven beneficial effects on blood flow, glycemic control and heart health and a cutting edge new in vitro screening technology.
“We are very happy with the Eureka/Eurostars commission’s trust in our project, as this clearly shows that they recognize our serious efforts in developing cutting edge food ingredients and food development technology at BioActor and our partner AdipoPhYt. This grant will enable us to further enhance our scientific knowledge on the effects of polyphenols on the human body and validate our product Cordiart®, which may even revolutionize the health market in cardiovascular disease prevention,” says Hans van der Saag, CEO BioActor.
About BioActor
BioActor, based in Maastricht, Netherlands, is a product development company that has developed a range of proprietary bioactive ingredients for the nutrition & healthcare industry. The company focuses on the development of innovative activities that address active living and healthy aging. The goal is to provide the nutrition & healthcare industry with science-based innovations that confer a real health benefit to the consumer.
Feel free to contact us via info@bioactor.com for more information on the possibilities Cordiart® has to offer.
Further information can be found on: www.cordiart.com
BioActor acquires Arabinoxylan-assets from DF3-WITAXOS and obtains positive EFSA opinion for its Arabinoxylan ingredient
BioActor acquires Arabinoxylan-assets from DF3-WITAXOS and obtains positive EFSA opinion for its Arabinoxylan ingredient
Press release
BioActor has acquired patents, know-how and clinical data relating to short-chain wheat arabinoxylans from DF3-WITAXOS. BioActor’s arabinoxylan ingredient obtained positive EFSA opinion for glycaemic control.
Arabinoxylan extract from wheat endosperm
BioActor BV announced today that it has acquired certain patents, manufacturing know-how and clinical data from DF3-WITAXOS. Moreover, DF3-WITAXOS’ managing director, Yann Dugenet, has joined BioActor as Director Product Development.
BioActor has already a long-chain Arabinoxylan ingredient derived from wheat endosperm in its portfolio, Naxus®, which recently obtained a positive EFSA Opinion for glycaemic control, and for which promising scientific evidence was recently obtained towards other health endpoints. Hans van der Saag, BioActor’s managing director comments; “The addition of short-chain Arabinoxylans which are derived from the same raw material source as our long chain Arabinoxylans-ingredient, further strengthens our portfolio of patented speciality fibers with clinically proven health effects”.
DF3 WITAXOS obtained excellent clinical data on prebiotic effects of its short-chain Arabinoxylans in a collaborative clinical trial with Institut Pasteur in Lille. Those results were consistent with earlier positive results from in-vitro experiments and in vivo tests on animal models. The integration of this ingredient in the Naxus® range of Arabinoxylan speciality fibers will allow for economies of scale in manufacturing and offers customers more choice in application possibilities.
EFSA has issued a positive opinion for a health claim on glycaemic control in connection with arabinoxylans produced from the wheat endosperm. EFSA proposes the following wording for the health claim: “Consumption of arabinoxylan contributes to a reduction of the glucose rise after a meal”. Naxus® is wheat endosperm derived arabinoxylan, which has been tested in several human studies and directly benefits from this health claim.
Naxus® is also being studied for immune modulation in the context of a 6 million Euro European research project – FIBEBIOTICS –, which is coordinated by Wageningen University (www.fibebiotics.eu).
About BioActor
BioActor, based in Maastricht, Netherlands, is a product development company that has developed a range of proprietary bioactive ingredients for the nutrition & healthcare industry. The company focuses on the development of innovative activities that address active living and healthy aging. The goal is to provide the nutrition & healthcare industry with science-based innovations that confer a real health benefit to the consumer.
Feel free to contact us via info@bioactor.com for more information on the possibilities Naxus® has to offer.
Further information can be found on: www.naxus.nl
